New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide

W. Boxtel, Ben Bulten, A.M. Mavinkurve-Groothuis, L. Bellersen, C.M. Mandigers, L.A. Joosten, L. Kapusta, Lioe-Fee de Geus-Oei, H.W. van Laarhoven

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Scopus)

Abstract

Objective: Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines. Methods: Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines. Results: 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = −0.564, p ≤ 0.01). Conclusion: The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.
Original languageUndefined
Pages (from-to)143-148
Number of pages6
JournalBiomarkers
Volume20
Issue number2
DOIs
Publication statusPublished - 2015

Keywords

  • METIS-312255
  • IR-99798

Cite this

Boxtel, W., Bulten, B., Mavinkurve-Groothuis, A. M., Bellersen, L., Mandigers, C. M., Joosten, L. A., ... van Laarhoven, H. W. (2015). New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. Biomarkers, 20(2), 143-148. https://doi.org/10.3109/1354750X.2015.1040839
Boxtel, W. ; Bulten, Ben ; Mavinkurve-Groothuis, A.M. ; Bellersen, L. ; Mandigers, C.M. ; Joosten, L.A. ; Kapusta, L. ; de Geus-Oei, Lioe-Fee ; van Laarhoven, H.W. / New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. In: Biomarkers. 2015 ; Vol. 20, No. 2. pp. 143-148.
@article{d5a25a759e834a939e90ed7013a6779f,
title = "New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide",
abstract = "Objective: Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines. Methods: Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines. Results: 29.1{\%} of patients showed abnormal biomarker levels: NT-proBNP in 18.2{\%}, TNF-α and Galectin-3 in 7.3{\%}. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = −0.564, p ≤ 0.01). Conclusion: The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.",
keywords = "METIS-312255, IR-99798",
author = "W. Boxtel and Ben Bulten and A.M. Mavinkurve-Groothuis and L. Bellersen and C.M. Mandigers and L.A. Joosten and L. Kapusta and {de Geus-Oei}, Lioe-Fee and {van Laarhoven}, H.W.",
year = "2015",
doi = "10.3109/1354750X.2015.1040839",
language = "Undefined",
volume = "20",
pages = "143--148",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "2",

}

Boxtel, W, Bulten, B, Mavinkurve-Groothuis, AM, Bellersen, L, Mandigers, CM, Joosten, LA, Kapusta, L, de Geus-Oei, L-F & van Laarhoven, HW 2015, 'New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide', Biomarkers, vol. 20, no. 2, pp. 143-148. https://doi.org/10.3109/1354750X.2015.1040839

New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. / Boxtel, W.; Bulten, Ben; Mavinkurve-Groothuis, A.M.; Bellersen, L.; Mandigers, C.M.; Joosten, L.A.; Kapusta, L.; de Geus-Oei, Lioe-Fee; van Laarhoven, H.W.

In: Biomarkers, Vol. 20, No. 2, 2015, p. 143-148.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide

AU - Boxtel, W.

AU - Bulten, Ben

AU - Mavinkurve-Groothuis, A.M.

AU - Bellersen, L.

AU - Mandigers, C.M.

AU - Joosten, L.A.

AU - Kapusta, L.

AU - de Geus-Oei, Lioe-Fee

AU - van Laarhoven, H.W.

PY - 2015

Y1 - 2015

N2 - Objective: Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines. Methods: Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines. Results: 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = −0.564, p ≤ 0.01). Conclusion: The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.

AB - Objective: Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines. Methods: Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines. Results: 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = −0.564, p ≤ 0.01). Conclusion: The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.

KW - METIS-312255

KW - IR-99798

U2 - 10.3109/1354750X.2015.1040839

DO - 10.3109/1354750X.2015.1040839

M3 - Article

VL - 20

SP - 143

EP - 148

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 2

ER -